http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Effect of Colored Potato Flakes Against Acetaminophen-induced Liver Damage in Rats
Kiyoshi Ohba,Shoko Watanabe,Kyu-Ho Han,Naoto Hashimoto,Takahiro Noda,Ken-ichiro Shimada,Hisashi Tanaka,Mitsuo Sekikawa,Michihiro Fukushima 한국식품과학회 2007 Food Science and Biotechnology Vol.16 No.3
We examined the hepatoprotective effects of colored potato flakes on acetaminophen(AAP)-induced liver damage in rats. F344/DuCrj (8 week-old) rats were fed a cholesterol-free diet with 54,9486 g of α-corn starch/100 g diet and were orally treated with 25% colored flakes of Kitamurasaki (KM: light purple), Northern Ruby (NR: red), and Queen (SQ: medium purple) potatoes co-administered with AAP (0.5 g/100 g diet)for 4 weeks. The hepatic thiobarbituric acid-reactive substances (TBARS) values in the KM, NR, and SQ group were significantly lower (p<0.05) than those in the control groups with and wothout AAP. Furthermore, the hepatic catalase, Mn-superoxide dismutase (SOD), and Cu/Zn-SOD mRNA levels in the KM, NR, and SQ groups were higher than those in the control groups with and without AAP. The present findings suggest that colored potato flakes are useful as a prophylactic agent against oxidative liver damage.
( Satoshi Motoya ),( Mamoru Watanabe ),( Hyo Jong Kim ),( Young Ho Kim ),( Dong Soo Han ),( Hirotoshi Yuasa ),( Junichi Tabira ),( Naoki Isogawa ),( Shoko Arai ),( Isao Kawaguchi ),( Toshifumi Hibi ) 대한장연구학회 2018 Intestinal Research Vol.16 No.2
Background/Aims: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAVE Induction were re-randomized to 52 weeks’ therapy with placebo, tofacitinib 5 mg BID, or tofacitinib 10 mg BID. Methods: We conducted post-hoc efficacy and safety analyses of East Asian patients in OCTAVE Induction 1 and 2 and OCTAVE Sustain. Results: A total of 121 East Asian (Japan, Korea, and Taiwan) patients were randomized in OCTAVE Induction 1 and 2 (placebo, n=26; tofacitinib 10 mg BID, n=95), and 63 in OCTAVE Sustain (placebo, n=20; tofacitinib 5 mg BID, n=22; tofacitinib 10 mg BID, n=21). At week 8 of OCTAVE Induction 1 and 2, 18.9% of patients (18/95) achieved remission with tofacitinib 10 mg BID versus 3.8% (1/26) with placebo. In OCTAVE Sustain, the week 52 remission rates were 45.5% (10/22), 47.6% (10/21), and 15.0% (3/20) with 5 mg BID, 10 mg BID, and placebo, respectively. Adverse event rates were similar between groups in OCTAVE Induction and numerically higher with tofacitinib in OCTAVE Sustain. Serious adverse event rates were similar across groups in all studies. Infections were numerically more frequent with tofacitinib than placebo. Increases in serum lipid levels were observed with tofacitinib. Conclusions: In East Asian patients with UC, tofacitinib demonstrated numerically greater efficacy versus placebo as induction and maintenance therapy, with a safety profile consistent with the global study population. ClinicalTrials.gov: NCT01465763; NCT01458951; NCT01458574. (Intest Res 2018;16:233-245)